Key Takeaways

  • The bottleneck in biotechnology has abandoned candidate discovery and shifted to human trials; candidate molecules doubled over the last ten years while approved drugs stayed flat at 50 per year.
  • Running clinical development demands heavy capital: a single Phase 2 trial costs between $60 million and $80 million, while full development reaches several hundred million dollars.
  • Formation Bio raised a $600 million asset financing fund structured as a hub-and-spoke model to purchase individual drug assets without acquiring entire corporate entities.
  • Small teams of drug developers paired with artificial intelligence orchestration can oversee dozens of clinical assets simultaneously by automating operational trial workflows.
  • Valuations follow strict step-functions dictated by Ben Liu's Clinical Proof of Concept Valuation Heuristic.

Ben Liu's Clinical Proof of Concept Valuation Heuristic

Stage 1: Pre-Clinical Discovery Candidate

A discovered drug isn't worth much because market discovery has experienced severe candidate abundance while clinical capacity remains fixed.

Stage 2: Post-Phase 2 Clinical Proof of Concept

Once a drug candidate demonstrates human clinical proof of concept post-Phase 2, the valuation heuristic is 1x peak projected sales (e.g., a $5 billion/year peak drug is valued at $5 billion).

Stage 3: Post-Phase 3 Completion

Once a drug candidate passes Phase 3 clinical trials, the valuation multiple increases to 2x to 3x peak projected sales.

When This Works (and When It Doesn't)

This framework applies when biotech companies calculate risk-adjusted expected value to decide whether to sell an asset to big pharma after Phase 2 (which has a 30% baseline success rate) versus spending tens of millions to independently fund Phase 3 (which carries a 40% chance of total failure to zero).

The math breaks down when market competition changes between trial phases. If three competitors enter Phase 3 ahead of your asset with comparable efficacy data, your peak projected sales denominator collapses before your trial concludes. The heuristic also fails for ultra-rare orphan indications where patient pools are so tiny that pricing power, rather than patient volume, dictates total sales. In those cases, regulatory reimbursement negotiations determine asset value far more than trial completion multiples.

What to Do With This

Map your pipeline using Liu's three-stage step function instead of a smooth discounted cash flow model. If you are developing a drug with an estimated $1 billion in peak annual sales, stop negotiating seed valuations on early discovery biology. An unvalidated molecule holds minimal enterprise value because the industry faces discovery candidate abundance.

Budget your runway specifically to survive through Phase 2 human data. Once you produce clean safety and efficacy data in diseased human patients, set your opening acquisition price at exactly $1 billion based on the 1x peak sales heuristic. Calculate the expected value of advancing to Phase 3 yourself: multiply a $2.5 billion outcome by the 60% probability of passing, then subtract the $100 million trial cost. If that risk-adjusted return does not clear your cost of capital, sell the asset immediately and recycle the proceeds into new clinical programs.